Advocates have claimed that CVS’s refusal to cover Yeztugo violates the Affordable Care Act (ACA), which requires insurers to ...

CVS Health will not cover Gilead's Yeztugo, generic name lenacapavir (LEN), citing "clinical, financial, and regulatory ...

CVS Health (NYSE:CVS), one of the leading health insurers in the U.S. and owner of the Pharmacy Benefit Manager Caremark, ...

Approved in June for people at high risk of HIV, Yeztugo was shown to be nearly 100% effective at preventing infection in ...

In 2014, Caremark was accused of manipulating how drug costs were reported, prompting Aetna and SilverScript to submit false ...

Primary care physicians and the state Senate’s health care point person are questioning a proposed partnership between Mass ...

The owner of the U.S.' largest pharmacy benefit manager is declining to cover Gilead Sciences’ long-acting HIV prevention ...

CVS Health is not entitled to coverage from insurers, including AIG and Chubb , against thousands of lawsuits over its role ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research ...

CVS Health CVS 0.0% (NYSE: CVS) reported its Q3 results earlier this month, with revenues and earnings beating the street estimates, and we believe that CVS stock is undervalued, as discussed below.

CVS Health stock (NYSE: CVS) has seen a fall of 10% in a month, compared with -4% returns for the broader S&P500 index. The company reported upbeat Q4 results last month, with revenue and earnings ...